Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases.

Chun YS, Laurent A, Maru D, Vauthey JN.

Lancet Oncol. 2009 Mar;10(3):278-86. doi: 10.1016/S1470-2045(09)70064-6. Review.

PMID:
19261256
2.

Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases.

Khan AZ, Morris-Stiff G, Makuuchi M.

J Hepatobiliary Pancreat Surg. 2009;16(2):137-44. doi: 10.1007/s00534-008-0016-z. Epub 2008 Dec 18. Review.

PMID:
19093069
3.

Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases.

Kandutsch S, Klinger M, Hacker S, Wrba F, Gruenberger B, Gruenberger T.

Eur J Surg Oncol. 2008 Nov;34(11):1231-6. doi: 10.1016/j.ejso.2008.01.001. Epub 2008 Feb 12.

PMID:
18272318
4.

Histological liver injury and surgical outcome after FOLFOX followed by a hepatectomy for colorectal liver metastases in Japanese patients.

Komori H, Beppu T, Baba Y, Horino K, Imsung C, Masuda T, Hayashi H, Okabe H, Ootao R, Watanabe M, Takamori H, Iyama K, Baba H.

Int J Clin Oncol. 2010 Jun;15(3):263-70. doi: 10.1007/s10147-010-0046-9. Epub 2010 Mar 19.

PMID:
20238233
5.

Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival.

Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, Giacchetti S, Paule B, Kunstlinger F, Ghémard O, Levi F, Bismuth H.

Ann Surg. 2004 Oct;240(4):644-57; discussion 657-8.

6.

Sinusoidal obstruction syndrome is a major feature of hepatic lesions associated with oxaliplatin neoadjuvant chemotherapy for liver colorectal metastases.

Rubbia-Brandt L, Mentha G, Terris B.

J Am Coll Surg. 2006 Jan;202(1):199-200. No abstract available.

PMID:
16377516
7.

Nodular regenerative hyperplasia (NRH) complicating oxaliplatin chemotherapy in patients undergoing resection of colorectal liver metastases.

Morris-Stiff G, White AD, Gomez D, Cameron IC, Farid S, Toogood GJ, Lodge JP, Prasad KR.

Eur J Surg Oncol. 2014 Aug;40(8):1016-20. doi: 10.1016/j.ejso.2013.09.015. Epub 2013 Nov 1.

PMID:
24370284
8.

The developing clinical problem of chemotherapy-induced hepatic injury.

Pilgrim CH, Thomson BN, Banting S, Phillips WA, Michael M.

ANZ J Surg. 2012 Jan-Feb;82(1-2):23-9. doi: 10.1111/j.1445-2197.2011.05789.x. Epub 2011 May 17. Review.

PMID:
22507491
9.

Hepatic complications following preoperative chemotherapy with oxaliplatin or irinotecan for hepatic colorectal metastases.

Morris-Stiff G, Tan YM, Vauthey JN.

Eur J Surg Oncol. 2008 Jun;34(6):609-14. Epub 2007 Aug 30. Review.

PMID:
17764887
10.

OncoSurge: a strategy for long-term survival in metastatic colorectal cancer.

Alberts S, Poston G.

Colorectal Dis. 2003 Nov;5 Suppl 3:20-8. Review.

PMID:
23573557
11.

[Predictive factors for histopathological liver injury in the patients who received preoperative systemic chemotherapy for colorectal liver metastases].

Kudo D, Tsutsumi S, Akasaka H, Jin H, Ohashi T, Muroya T, Hasebe T, Sakamoto Y, Ishido K, Koyama M, Toyoki Y, Murata A, Narumi S, Kijima H, Hakamada K.

Gan To Kagaku Ryoho. 2009 Nov;36(12):2025-7. Japanese.

PMID:
20037312
12.

Multicenter phase II study of modified FOLFOX6 as neoadjuvant chemotherapy for patients with unresectable liver-only metastases from colorectal cancer in Japan: ROOF study.

Takahashi T, Shibata Y, Tojima Y, Tsuboi K, Sakamoto E, Kunieda K, Matsuoka H, Suzumura K, Sato M, Naganuma T, Sakamoto J, Morita S, Kondo K.

Int J Clin Oncol. 2013 Apr;18(2):335-42. doi: 10.1007/s10147-012-0382-z. Epub 2012 Mar 2.

PMID:
22383023
13.

Chemotherapy for the conversion of unresectable colorectal cancer liver metastases to resection.

Power DG, Kemeny NE.

Crit Rev Oncol Hematol. 2011 Sep;79(3):251-64. doi: 10.1016/j.critrevonc.2010.08.001. Epub 2010 Oct 22. Review.

PMID:
20970353
14.

[HEMIHEPATECTOMY FOR RESECTABLE HEPATIC METASTASIS FROM COLORECTAL CANCER WITH POOR PROGNOSIS].

Patyutko YI, Kotelnikov AG, Mamontov KG, Podluzhny DV, Ponomarenko AA.

Vopr Onkol. 2015;61(3):439-47. Russian.

PMID:
26242159
15.

Risk factors for chemotherapy-associated liver injuries: A multivariate analysis of a group of 146 patients with colorectal metastases.

Brouquet A, Benoist S, Julie C, Penna C, Beauchet A, Rougier P, Nordlinger B.

Surgery. 2009 Apr;145(4):362-71. doi: 10.1016/j.surg.2008.12.002. Epub 2009 Feb 23.

PMID:
19303984
16.

Chemotherapy and molecular-targeted treatment for unresectable hepatic metastases: a Japanese perspective.

Shimada Y.

J Hepatobiliary Pancreat Sci. 2012 Sep;19(5):515-22. doi: 10.1007/s00534-012-0517-7. Review.

PMID:
22588204
17.

Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases.

Zorzi D, Laurent A, Pawlik TM, Lauwers GY, Vauthey JN, Abdalla EK.

Br J Surg. 2007 Mar;94(3):274-86. Review.

PMID:
17315288
18.

Updated options for liver-limited metastatic colorectal cancer.

Alberts SR.

Clin Colorectal Cancer. 2008 Dec;7 Suppl 2:S58-62. doi: 10.3816/CCC.2008.s.009. Review.

PMID:
19064408
19.

Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases.

Aloia T, Sebagh M, Plasse M, Karam V, Lévi F, Giacchetti S, Azoulay D, Bismuth H, Castaing D, Adam R.

J Clin Oncol. 2006 Nov 1;24(31):4983-90.

PMID:
17075116
20.

mRNA gene expression correlates with histologically diagnosed chemotherapy-induced hepatic injury.

Pilgrim CH, Brettingham-Moore K, Pham A, Murray W, Link E, Smith M, Usatoff V, Evans PM, Banting S, Thomson BN, Michael M, Phillips WA.

HPB (Oxford). 2011 Nov;13(11):811-6. doi: 10.1111/j.1477-2574.2011.00365.x. Epub 2011 Aug 2.

Supplemental Content

Support Center